Marshall Wace
AGRX

Marshall Wace’s Agile Therapeutics AGRX Stock Holding History

Marshall Wace’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-65
Closed -$1.27M – 1230
2015
Q4 		$1.27M Buy
65
+3
+5% +$47.5K 0.01% 659
2015
Q3 		$834K Hold
62
– – 0.01% 648
2015
Q2 		$1.06M Buy
62
+22
+55% +$469K 0.01% 595
2015
Q1 		$749K Buy
+40
New +$701K 0.01% 618

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Marshall Wace's AGRX Position: Q1 2016 in Review

Marshall Wace sold out of Agile Therapeutics (AGRX) in Q1 2016, closing a stake of 65 shares — an estimated $1.27M sold.

Marshall Wace first reported a position in AGRX in Q1 2015 and held it in 4 quarters. The position peaked at $1.27M in Q4 2015. 48 funds tracked by Wall St. Rank hold AGRX as of Q1 2016.

  • Marshall Wace reported no remaining Agile Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Marshall Wace sold 65 Agile Therapeutics shares in Q1 2016, an estimated $1.27M.
  • Marshall Wace first reported a position in Agile Therapeutics in Q1 2015 and held it in 4 quarters.
  • Marshall Wace's Agile Therapeutics position peaked at $1.27M in Q4 2015.
  • 48 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2016.

Based on Marshall Wace's 13F filing for Q1 2016, filed 13 May 2016.